Chronic inflammatory demyelinating polyneuropathy (CIDP) is thought to be an autoimmune condition. When you have CIDP, your immune system sees your nerves as foreign and attacks them. The attack ...

The FDA approval was based on data from two Phase 3 studies, PATH and PRIMA. CSL Behring announced that the Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human ...

KING OF PRUSSIA, Pa., Feb. 11, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin ...

Privigen (human immunoglobulin G) is a prescription drug used to treat certain immune system conditions. The drug comes as an intravenous (IV) infusion (an injection into a vein given over time).

The prescribed dosage for Privigen (human immunoglobulin g) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical ...

June 27, 2012 Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, ...

Data published online in the current edition of Journal of Clinical Immunology demonstrates that Privigen TM, the new liquid immune globulin intravenous (human) 10 percent product from CSL Behring, is ...

CSL Behring announced that the FDA has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen (immune globulin intravenous [Human] liquid) from 24 months to ...

KING OF PRUSSIA, Pa. — The Food and Drug Administration has approved a new vial size for a drug made by CSL Behring to treat a bleeding disorder and an immune disorder, the company said Thursday. The ...